Investment Rating - The report maintains an "Overweight" rating for the agriculture, forestry, animal husbandry, and fishery industry [1][46] Core Insights - The profitability of pig farming has shown signs of recovery, with self-breeding pig farming profits turning positive [30] - The industry has slightly underperformed compared to the CSI 300 index, with a decline of 0.72% from January 5 to January 15, 2026, lagging behind the index by approximately 3.34 percentage points [14] - The report highlights the potential for price recovery in pig farming due to seasonal demand, and emphasizes the importance of capacity reduction in the breeding sector [46][48] Industry Performance Overview - The SW agriculture, forestry, animal husbandry, and fishery industry index has a current PB ratio of approximately 2.63, indicating a slight decline in valuation and positioning at about 59.2% of the historical average since 2006 [21] - Among the sub-sectors, animal health, fishery, agricultural product processing, and planting recorded positive returns, with increases of 8.52%, 4.59%, 1.77%, and 0.45% respectively, while feed and breeding sectors saw declines of 0.99% and 2.34% [17][18] Key Industry Data - The average price of external three-breed pigs fluctuated from 12.86 CNY/kg to 12.48 CNY/kg and then rebounded to 12.76 CNY/kg between January 2 and January 15, 2026 [22] - As of January 15, 2026, the average price of corn was 2363.82 CNY/ton and soybean meal was 3184 CNY/ton, both showing a recent increase [27] - The profit for self-breeding pig farming reached 7.39 CNY/head, while the profit for purchased pig farming was 48.35 CNY/head, indicating a shift from loss to profit [30] Company Insights - Key companies to watch include Muyuan Foods (002714), Wens Foodstuff Group (300498), and Shengnong Development (002299), which are positioned well for potential growth in the sector [48][49] - The report notes that the domestic pet market has growth potential, with exports expected to maintain rapid growth, highlighting opportunities in leading domestic companies [48]

Core Viewpoint - The animal health sector experienced a rise of 0.93% on January 16, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4101.91, down 0.26% [1]. - The Shenzhen Component Index closed at 14281.08, down 0.18% [1]. Group 2: Individual Stock Performance - BioShares (600201) led the gains with a closing price of 17.61, up 3.53%, and a trading volume of 480,000 shares, amounting to a transaction value of 840 million yuan [1]. - Other notable performers included: - Huisheng Bio (300871) at 26.03, up 1.36%, with a transaction value of 434 million yuan [1]. - Xianfeng Holdings (002141) at 3.76, up 1.35%, with a transaction value of 8.13 million yuan [1]. - Ruipu Bio (300119) at 20.15, up 0.90%, with a transaction value of 110 million yuan [1]. - Shunlian Bio (688098) at 9.60, up 0.63%, with a transaction value of 40.84 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 112 million yuan from institutional investors, while retail investors experienced a net outflow of 68.65 million yuan [2]. - The capital flow for individual stocks showed: - BioShares had a net inflow of 75.95 million yuan from institutional investors [3]. - Huisheng Bio had a net inflow of 19.63 million yuan from institutional investors [3]. - Xianfeng Holdings had a net inflow of 16.40 million yuan from institutional investors [3].

专题：第七届"中国造隐形冠军"长青恳谈会 来源：中外管理传媒 文：杨光（中外管理传媒社长、总编，"中国造隐形冠军"评选发起人，"中国上市隐形冠军俱乐部"秘书 长） 2025年是中国"十四五"计划的收官年，2026年将是"十五五"规划的开启年，必将是未来中国经济和中国 企业高质量可持续发展的新起点，也将是中国隐形冠军企业（包括已上市隐形冠军企业）进一步健康发 展的新起点。 已发布的"十五五"规划中，围绕已上市的专精特新企业所创造出的骄人数据，进一步提出了如下核心发 展要求： 一、强化企业创新主体地位。进一步提升研发投入强度，专精特新"小巨人"企业上年度平均研发投入超 3000万元，平均研发强度超过7%，远高于规上工业企业平均水平。支持企业围绕"打造新动能、攻坚新 技术、开发新产品"加大科技创新投入，不断夯实企业立身之本。 二、提升产业链配套能力。支持企业围绕重点领域龙头企业产业链供应链需求，加大产业化投入，着力 提升产业链供应链韧性和安全水平。专精特新"小巨人"企业超六成处于工业基础领域，超七成深耕行业 10年以上，超八成进入了战略性新兴产业链，在提升产业链供应链稳定性中发挥重要作用。 三、完善多层次资本市场服 ...

Market Overview - The animal health sector experienced a decline of 0.16% on January 15, with the driving force leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - The following stocks in the animal health sector showed notable performance: - *ST Lvkang (002868)*: Closed at 37.13, up 5.01% with a trading volume of 32,900 shares and a turnover of 120 million yuan [1] - Jinhe Biology (002688): Closed at 6.34, up 1.28% with a trading volume of 329,000 shares and a turnover of 207 million yuan [1] - Huisheng Biology (300871): Closed at 25.68, up 0.63% with a trading volume of 188,300 shares and a turnover of 489 million yuan [1] - Other stocks like Pulaike (603566) and Ruipu Biology (300119) also showed slight increases [1] Capital Flow Analysis - The animal health sector saw a net outflow of 32.17 million yuan from institutional investors, while retail investors had a net inflow of 44.53 million yuan [2] - The following stocks had significant capital flow: - Jinhe Biology (002688): Net inflow of 13.58 million yuan from institutional investors, but net outflows from retail investors [3] - *ST Lvkang (002868)*: Net inflow of 6.86 million yuan from institutional investors, with outflows from retail investors [3] - Other stocks like Shenglian Biology (688098) and Driving Force (920275) experienced net outflows from both institutional and retail investors [3]

Group 1 - The core viewpoint of the news is that Reap Bio has been recognized as a "Green Factory" for 2025 by the Tianjin Municipal Bureau of Industry and Information Technology, highlighting its leadership in promoting green transformation in the industry [1] - The recognition reflects Reap Bio's strong manufacturing capabilities and its commitment to integrating green and low-carbon development into its core business strategy since its establishment [1] - The evaluation process for the recognition included stringent requirements on energy consumption levels, environmental indicators, and green management systems, prioritizing enterprises with a solid foundation in green low-carbon development [1] Group 2 - In recent years, Reap Bio has aimed to build "smart factories and digital factories," implementing a lean green management system and increasing investments in the integration of intelligence, digitalization, and greening [2] - The company has embedded low-carbon standards throughout the entire process from raw material procurement to production and finished product delivery, utilizing smart production equipment and real-time monitoring systems for energy consumption and emissions [2] - Reap Bio's practices align with the national "14th Five-Year Plan" recommendations to accelerate the high-end, intelligent, and green development of the manufacturing industry, and the company plans to continue its commitment to sustainable development and contribute to high-quality manufacturing and carbon neutrality goals [2]

Market Overview - The animal health sector experienced a decline of 0.44% on January 14, with Haili Biological leading the drop [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.39, up 10.65% on a trading volume of 112,300 shares and a turnover of 118 million yuan [1] - Huisheng Biological (code: 300871) closed at 25.52, up 1.84% with a trading volume of 270,100 shares and a turnover of 696 million yuan [1] - Major decliners included: - Haili Biological (code: 603718) closed at 6.55, down 1.65% with a trading volume of 237,400 shares and a turnover of 157 million yuan [2] - Zhongmu Co., Ltd. (code: 600195) closed at 7.92, down 1.61% with a trading volume of 201,400 shares and a turnover of 161 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 140 million yuan from institutional investors, while retail investors experienced a net inflow of 52.14 million yuan [2] - The detailed capital flow for selected stocks showed: - Huisheng Biological had a net inflow of 23.06 million yuan from institutional investors [3] - ST Green Kang (code: 002868) faced a significant net outflow of 5.87 million yuan from institutional investors [3]

Investment Rating - The industry is rated as "Leading the Market - A" with a maintained rating [5]. Core Views - The recent pig prices are expected to fluctuate within a range, with a focus on changes in production capacity [19][21]. - The white feather chicken market is experiencing a supply-demand mismatch, with stable prices but cautious market sentiment [33]. - The aquaculture sector shows stable prices, presenting potential investment opportunities [47]. Summary by Sections 1. Weekly Market Review - The agricultural sector increased by 0.98% during the latest trading week, ranking 29th among the primary industries [12]. - The animal health sector saw significant gains, with notable increases in specific stocks [15]. 2. Industry Data Tracking 2.1. Pig Farming - The average price of live pigs is 12.49 CNY/kg, with a week-on-week increase of 1.54% and a two-week increase of 4.22% [18]. - The average price of piglets is 363 CNY/head, stable over the past two weeks [19]. - The average daily slaughter volume of pigs is 226,500 heads, showing a week-on-week decrease of 5.12% [19]. 2.2. Poultry Farming - The average price of white feather chicken is 7.64 CNY/kg, down 1.04% week-on-week [33]. - The price of chicken seedlings is 3.59 CNY/bird, up 1.70% week-on-week [33]. - The market is stable, but there is a notable increase in inventory levels due to weak demand [33]. 2.3. Planting Sector - The average price of corn is 2,352.77 CNY/ton, with a slight increase of 0.02% week-on-week [42]. - The average price of domestic wheat is 2,512.98 CNY/ton, down 0.12% week-on-week [42]. - The average price of domestic soybeans is 4,048.42 CNY/ton, up 0.50% week-on-week [42]. 2.4. Aquaculture Sector - The average price of carp is 20.00 CNY/kg, stable week-on-week, with a year-on-year increase of 11.11% [47]. - The average price of crab is 260.00 CNY/kg, showing a significant year-on-year increase of 30.00% [47]. - The average price of shrimp is 320.00 CNY/kg, stable week-on-week but down 11.11% year-on-year [47].

Group 1 - The core point of the article is that Reap Bio (300119) has reported a total of 25,854 shareholders as of January 9, 2026 [1]

Core Insights - The animal health sector experienced a rise of 1.09% on January 13, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Stock Performance - Huisheng Biological (300871) closed at 25.06, up 8.39%, with a trading volume of 276,700 shares and a transaction value of 700 million [1] - Other notable performers included: - Qudongli (920275) at 65.6, up 3.99% [1] - Haili Biological (603718) at 6.66, up 1.99% [1] - Xianfeng Holdings (002141) at 3.77, up 1.34% [1] - Shunlian Biological (688098) at 9.78, up 1.03% [1] Capital Flow - The animal health sector saw a net inflow of 34.99 million from institutional investors, while retail investors contributed a net inflow of 30.94 million [2] - However, speculative funds experienced a net outflow of 65.94 million [2] Individual Stock Capital Flow - Major net inflows were observed in: - Biological Shares (600201) with a net inflow of 39.54 million [3] - Jinhe Biological (002688) with a net inflow of 13.45 million [3] - Xianfeng Holdings (002141) with a net inflow of 10.20 million [3] - Conversely, significant net outflows were noted in: - Biological Shares (600201) with a net outflow of 48.25 million from speculative funds [3] - Jinhe Biological (002688) with a net outflow of 1.46 million from retail investors [3]

Core Viewpoint - Ruipai Pet Hospital Management Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to become the first publicly listed pet medical company in China, marking a significant shift from "wild growth" to "standardized capitalization" in the pet medical industry [1][2] Industry Capitalization Acceleration - The pet medical industry is transitioning to a new phase of "standardized capitalization," with Ruipai's IPO seen as a pivotal moment that could establish valuation standards and operational benchmarks for the industry [2][3] - Founded in 2012, Ruipai is the first nationwide chain pet medical service provider in China, operating 548 hospitals as of June 30, 2025, and holding a 4.8% market share in the pet medical sector by revenue [2][3] Financial Performance - Ruipai's revenue grew from 1.455 billion yuan in 2022 to 1.585 billion yuan in 2023, and is projected to reach 1.758 billion yuan in 2024, with gross profit also increasing annually [3][4] - The company achieved a net profit of 15.5 million yuan in the first half of 2025, marking a turnaround from previous losses [4][5] Growth Challenges - Despite rapid growth through acquisitions, Ruipai faces challenges such as short-term profitability pressures and insufficient growth momentum, necessitating a transformation of its expansion model [1][6] - The company has experienced a significant reduction in the number of new acquisitions, indicating potential difficulties in finding quality targets for expansion [6][7] Competitive Landscape - Ruipai's competitive advantage lies in its unique Veterinary Development Partners (VDP) model and a three-tier medical system, which have contributed to its high gross margin of 24.8% [4][5] - However, the company is heavily reliant on acquisitions, with 78% of its stores acquired, leading to integration challenges and varying service standards across locations [7][8] Future Outlook - Industry experts suggest that Ruipai must shift from an acquisition-driven growth strategy to a dual approach of internal growth and acquisitions to enhance its competitive sustainability [9][10] - The company faces financial risks, including significant goodwill and high operational costs, which could impact its profitability if not managed effectively [8][9]